Study: Proton Radiation Therapy in Treating Patients With Prostate Cancer

Status: Recruiting

Sponsor: Abramson Cancer Center of the University of Pennsylvania

ClinicalTrials.gov Link: Click Here

Study: Preoperative Radiation Therapy for High Risk Prostate Cancer

Status: Recruiting

Sponsor: Duke University

ClinicalTrials.gov Link: Click Here

Study: Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

Status: Recruiting

Sponsor: University of Florida

ClinicalTrials.gov Link: Click Here

Study: Ketoconazole and Dexamethasone in Prostate Cancer (Keto/Dex)

Status: Recruiting

Sponsor: University of California, San Francisco

ClinicalTrials.gov Link: Click Here

Study: MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate

Status: Recruiting

Sponsor: Abramson Cancer Center of the University of Pennsylvania

ClinicalTrials.gov Link: Click Here

Study: Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Status: Recruiting

Sponsor: Memorial Sloan-Kettering Cancer Center

ClinicalTrials.gov Link: Click Here

Study: Abiraterone Acetate, Prednisone, and Leuprolide Acetate Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer

Status: NOT YET Recruiting

Sponsor: Fred Hutchinson Cancer Research Center

ClinicalTrials.gov Link: Click Here

Study: Hormone Therapy With or Without Bevacizumab in Treating Patients With Recurrent Prostate Cancer

Status: NOT YET Recruiting

Sponsor: Cancer Institute of New Jersey

ClinicalTrials.gov Link: Click Here

Study: Abiraterone Acetate Plus Prednisone Drug-Drug Interaction With Dextromethorphan and Theophylline Treating Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Sponsor: Cougar Biotechnology

ClinicalTrials.gov Link: Click Here

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival

Click for News Release

Shorter Radiation Course as Effective as Standard Therapy For Prostate Cancer Recurrence

Click Here for News Release

Shorter Radiation Course Stops Cancer Growth in High-Risk Prostate Cancer Patients

Click Here for News Release

Dendreon Completes Submission of Biologics License Application for PROVENGE

Click for News Release

Adding Proton Therapy ‘Boost’ to X-Ray Radiation Therapy Reduces Prostate Cancer Recurrences

Click Here for News Release

FDA Grants Additional Fast Track Designation for OGX-011 in Combination with First Line Chemotherapy

BOTHELL, WA, and VANCOUVER, Oct. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment. OncoGenex had previously received Fast Track Designation for second-line docetaxel treatment with OGX-011 in combination with docetaxel for treatment of progressive metastatic prostate cancer following docetaxel.

Click for News Release

Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 percent of patients at a median follow-up of two years. Published rates of erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, range from 50-70 percent.

Click Here for News Release

Study: A Study of the Safety and Efficacy of Single-agent CNTO 888 (an Anti CC-Chemokine Ligand 2 [CCL2]) in Patients With Metastatic Prostate Cancer

Brief Description:  The purpose of this study is to determine the safety and effectiveness of the study drug CNTO 888 in patients with metastatic castrate-resistant prostate cancer.

Status: Recruiting

Sponsor: Centocor, Inc.

ClinicalTrials.gov Link: Click Here

Study: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

Brief Description:  This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy

Status: Recruiting

Sponsor: Medivation, Inc.

ClinicalTrials.gov Link: Click Here

Study: Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Brief Description: The purpose of this trial is to evaluate a short course of very focused (stereotactic) external beam radiation therapy for the treatment of early stage prostate cancer.  The investigators will gather scientific information about the tolerance and side effects this type of radiation.  The investigators will then compare these results with those of standard 8 week course of external beam radiation therapy to see if this study treatment is equally or more effective in treating prostate cancer.

Status: Recruiting

Sponsor: San Diego Radiosurgery

ClinicalTrials.gov Link: Click Here

Study: Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy (PR06)

Brief Description: Patients are being asked to take part in this study because they had prostate cancer that was treated surgically and it has been determined that they might have a greater risk of their prostate cancer returning or their prostate cancer has already returned.  The purpose of this study is to see what effects, good and/or bad, image guided proton based radiation therapy, and/or conventional radiation therapy and hormonal therapy (if applicable), has on the patient’s prostate cancer that has already returned or the risk of their prostate cancer returning.  With the patient’s consent, this study will also look at their prostate cancer tissue that was removed during their surgery for information that may help to treat prostate cancer in the future.

Status: Recruiting

Sponsor: University of Florida

ClinicalTrials.gov Link: Click Here

Click for News Release

Click for News Release

Click for News Release

Study:  Study Using WST11 In Patients With Localized Prostate Cancer (PCM202)

Brief Description: The aim of this study is to determine the optimal treatment conditions (WST11 dose and light energy dose) to achieve ablation in one lobe of the prostate and to evaluate the safety and quality of life of WST11 medicated Vascular-Targeted Photodynamic therapy (VTP) in men with localized prostate cancer.

Status: Recruiting

Sponsor: Steba Biotech S.A.

ClinicalTrials.gov Link: Click Here

Study:  Pazopanib as Second Line Therapy in Patients With Prostate Cancer Refractory to Total Androgen Blockade

Status: Recruiting

Sponsor: Illinois CancerCare, P.C.

ClinicalTrials.gov Link: Click Here

Soccer Hall of Famer Marcelo Balboa Encourages Men to ‘Team Up Against Prostate Cancer’

Click for News Release

Study:  Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer

Status: Recruiting

Sponsor: Beth Israel Medical Center

ClinicalTrials.gov Link: Click Here

Study: Neoadjuvant Abiraterone Acetate plus leuprolide acetate in men with localized high risk prostate cancer

Status: Not yet recruiting*

Anticipated start or recruitment: July 2009

Sponsor: Cougar Biotechnology

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the “subscribe” link at the top of the page.

Study:  Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg (CAMON)

Status: Recruiting

Sponsor: AstraZeneca

ClinicalTrials.gov Link: Click Here

Study:  Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-Resistant Prostate Cancer

Status: Recruiting

Sponsor: Weill Medical College of Cornell University

ClinicalTrials.gov Link: Click Here

Study:  Hypothermic Nerve Sparing Radical Prostatectomy

Status: Recruiting (by invitation)

Sponsor: University of California, Irvine

ClinicalTrials.gov Link: Click Here

Medivation announces positive new efficacy data from Phase 1-2 trial of MDV3100 in advanced prostate cancer patients

Click for News Release

Study:  QT/QTc and Multi-Dose Pharmacokinetic (PK) Study of Abiraterone Acetate

Status: Recruiting

Sponsor: Cougar Biotechnology

ClinicalTrials.gov Link: Click Here

Ascenta Therapeutics announces presentation of promising results from clinical trials of AT-101 in prostate, brain, and lung cancers at 2009 ASCO annual meeting

Click for News Release

AEtna Zentaris presents data supporting evaluation of AEZS-108 in prostate cancer at ASCO meeting

Click for News Release

PROSTVAC data presented at ASCO meeting demonstrates the potential for significant increases in life expectancy in late-state prostate cancer

Click for News Release

OncoGenex Pharmaceuticals announces OGX-011 treatment provides survival benefit in randomized Phase 2 trial in advanced metastatic prostate cancer

Click for News Release

Study:  GM-CSF in Treating Patients With Relapsed Prostate Cancer

Status: Not yet recruiting*

Anticipated start of recruitment: Unknown

Sponsor: The Cleveland Clinic, National Cancer Institute (NCI)

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Study:  Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer

Status: Recruiting

Sponsor: National Cancer Institute (NCI)

ClinicalTrials.gov Link: Click Here

Study:  RNActive®-Derived Therapeutic Vaccine

Status: Recruiting

Sponsor: University of Florida, CureVac GmbH

ClinicalTrials.gov Link: Click Here

Study:  Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC)

Status: Not yet recruiting*

Anticipated start of recruitment: August 2009

Sponsor: Dendreon

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Team ZERO to Run to End Prostate Cancer in 2009 ING New York City Marathon:

Click for News Release

Clinical Trials Advocacy Group for Prostate Cancer partners with “Prostate Cancer InfoLink”

Prostate Cancer InfoLink “offering the most user-friendly personalized prostate cancer information on the web” has agreed to feature CTAG for Prostate Cancer as its default search tool for prostate cancer clinical trials.

To view the Prostate Cancer InfoLink webpage Click Here

OncoGenex receives confirmation from FDA on the design of a second Phase 3 trial evaluating OGX-011 for the treatment of advanced prostate cancer:

Click for News Release

Data presented at AUA demonstrate PROVENGE significantly prolongs survival for men with advanced prostate cancer in pivotal Phase 3 IMPACT study:

Click for News Release

Ferring Pharmaceuticals launches Phase IIIB trial of Degarelix as intermittent therapy:

Click for News Release

Study: Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

Status: Not yet recruiting*

Anticipated start of recruitment: March 2009

Sponsor: Barbara Ann Karmanos Cancer Institute

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment. To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Study: Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Status: Not yet recruiting*

Anticipated start of recruitment: July 2009

Sponsor: Duke University

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Study: A Two-Dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

 Status: Not yet recruiting*

 Anticipated start of recruitment: Unknown

 Sponsor: Johns Hopkins University

 ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.   To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Study: Abiraterone Acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer

Status: Not yet recruiting*

Anticipated start or recruitment: April 2009

Sponsor: Cougar Biotechnology

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Study: Investigation of the effect of Degarelix in terms of prostate volume reduction in prostate cancer patients

Status: Not yet recruiting*

Anticipated start of recruitment: May 2009

Sponsor: Ferring Pharmaceuticals

ClinicalTrials.gov Link: Click Here

* CTAG will create a listing for this clinical trial once it has been officially opened to patient recruitment.  To receive notification, subscribe to our newsfeed by clicking the icon at the top of the page.

Stanford study on CyberKnife Radiosurgery for prostate cancer demonstrates 100 percent PSA response at 33 months:

Click for News Release